1. Home
  2. NRXP vs NEPH Comparison

NRXP vs NEPH Comparison

Compare NRXP & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRXP
  • NEPH
  • Stock Information
  • Founded
  • NRXP 2015
  • NEPH 1997
  • Country
  • NRXP United States
  • NEPH United States
  • Employees
  • NRXP N/A
  • NEPH N/A
  • Industry
  • NRXP Biotechnology: Pharmaceutical Preparations
  • NEPH Medical/Dental Instruments
  • Sector
  • NRXP Health Care
  • NEPH Health Care
  • Exchange
  • NRXP Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • NRXP 58.5M
  • NEPH 57.2M
  • IPO Year
  • NRXP N/A
  • NEPH 2004
  • Fundamental
  • Price
  • NRXP $2.92
  • NEPH $5.70
  • Analyst Decision
  • NRXP Strong Buy
  • NEPH Strong Buy
  • Analyst Count
  • NRXP 5
  • NEPH 2
  • Target Price
  • NRXP $31.40
  • NEPH $5.50
  • AVG Volume (30 Days)
  • NRXP 435.6K
  • NEPH 84.7K
  • Earning Date
  • NRXP 11-13-2025
  • NEPH 11-05-2025
  • Dividend Yield
  • NRXP N/A
  • NEPH N/A
  • EPS Growth
  • NRXP N/A
  • NEPH N/A
  • EPS
  • NRXP N/A
  • NEPH 0.12
  • Revenue
  • NRXP N/A
  • NEPH $16,684,000.00
  • Revenue This Year
  • NRXP N/A
  • NEPH $24.38
  • Revenue Next Year
  • NRXP $395.09
  • NEPH $10.16
  • P/E Ratio
  • NRXP N/A
  • NEPH $48.16
  • Revenue Growth
  • NRXP N/A
  • NEPH 21.16
  • 52 Week Low
  • NRXP $1.12
  • NEPH $1.38
  • 52 Week High
  • NRXP $6.01
  • NEPH $5.98
  • Technical
  • Relative Strength Index (RSI)
  • NRXP 41.65
  • NEPH 62.03
  • Support Level
  • NRXP $3.05
  • NEPH $4.86
  • Resistance Level
  • NRXP $3.32
  • NEPH $5.97
  • Average True Range (ATR)
  • NRXP 0.22
  • NEPH 0.50
  • MACD
  • NRXP -0.05
  • NEPH 0.01
  • Stochastic Oscillator
  • NRXP 0.74
  • NEPH 80.82

About NRXP NRX Pharmaceuticals Inc.

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of its revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: